Copyright
©The Author(s) 2018.
World J Gastrointest Oncol. Jan 15, 2018; 10(1): 31-39
Published online Jan 15, 2018. doi: 10.4251/wjgo.v10.i1.31
Published online Jan 15, 2018. doi: 10.4251/wjgo.v10.i1.31
Table 5 Relationship between adjuvant treatment and the prognosis of T4bN1-3M0/TxN3bM0 gastric cancer patients
| Treatment | n | Median DFS (mo) | 3-yr DFS (%) | P value | MedianOS (mo) | 5-yr OS (%) | P value | |
| Adjuvant chemotherapy | Yes | 164 | 12.3 | 10.4% | 0.000 | 25.7 | 16.1% | 0.532 |
| No | 12 | 2.8 | 0.0% | 18.7 | 22.2% | |||
| Chemotherapy | Mono- therapy | 10 | 6.7 | 0.0% | 0.583 | 20.3 | 0.0% | 0.661 |
| Regimen | Doublet | 134 | 12.0 | 5.3% | 26.3 | 17.4% | ||
| Triple | 20 | 13.0 | 5.3% | 29.7 | 18.5% | |||
| Adjuvant chemotherapy time | ≥ 6 mo | 39 | 23.2 | 20.2% | 0.000 | 40.2 | 25.0% | 0.001 |
| < 6 mo | 125 | 9.9 | 7.3% | 21.6 | 13.4% | |||
- Citation: Wang QW, Zhang XT, Lu M, Shen L. Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer. World J Gastrointest Oncol 2018; 10(1): 31-39
- URL: https://www.wjgnet.com/1948-5204/full/v10/i1/31.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v10.i1.31